Outpatient ASCT for Myeloma Found Safe, Effective With Proper Patient Selection – Cancer Therapy Advisor

Administering high-dose chemotherapy and autologous stem cell transplant (ASCT) in an outpatient setting was safe and feasible for patients with multiple myeloma, according to the results of a single-center study.

Researchers at Vancouver General Hospital, which has the sole hematopoietic transplant program in British Columbia, Canada, have been conducting outpatient ASCT for patients with plasma cell disorders since 2004.

Patients with poorer performance status and cardiac amyloidosis are followed more closely and have a lower threshold for hospital admission, they noted.

They conducted a retrospective study of these procedures performed from 2007 to 2016 to analyze safety and outcomes. During this time, 724 patients underwent 752 ASCTs. The median age of patients was 60. The majority of patients underwent conditioning with melphalan 200 mg/m2.

Patients were recommended for transplant for myeloma (96.9%), amyloidosis (2.4%), and POEMS syndrome (0.7%). Median time from diagnosis to transplant was 5 months.

Approximately one-third of patients required admission to the inpatient ward within the first 30 days after transplant. The median time to this admission was 9 days, and patients were in the inpatient ward for a median of 6 days. The most common causes of hospitalization were febrile neutropenia and mucositis.

However, the overall transplant-related mortality was low at 0.4%. The day 100 all-cause mortality was also low at 0.9%.

Outpatient ASCTs are safe and result in decreased resource utilization, the researchers wrote. Patient selection, appropriate prophylactic antibiotic regimen, a well-equipped and staffed daycare unit to treat infectious complications and administer transfusion blood products, and a multidisciplinary team is essential to deliver this model of care.


Kodad SG, Sutherland H, Limvorapitak W, et al. Outpatient autologous stem cell transplants for multiple myeloma: analysis of safety and outcomes in a tertiary care center [published online October 8, 2019]. Clin Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2019.09.619

See the rest here:
Outpatient ASCT for Myeloma Found Safe, Effective With Proper Patient Selection - Cancer Therapy Advisor

Cell Isolation Market To Reach USD 18.26 Billion By 2026 | Reports And Data – GlobeNewswire

New York, Nov. 25, 2019 (GLOBE NEWSWIRE) -- In the recent years, interest of biotechnology companies and scientists in cancer and stem cell research has increased. Advanced cell isolation products deliver improved separation of biological molecules including proteins, nucleic acids, chromatin and protein complexes for further analysis. In addition to this, there has been an increase in demand for personalized medicine. This has further helped this market grow.

According to the current analysis of Reports and Data, The global cell isolation market was valued at USD 4.9 billion in 2018 and is expected to reach USD 18.28 billion by the year 2026, at a CAGR of 17.7%. Cell isolation is the process of extracting a specialized cell from a heterogeneous mixture and then process it to identify its properties and replicate it to develop new therapies. For the determination of appropriate separation technique, an exhaustive analysis of the cell size, cell behavior, density, antigen status, and hydrophobic surface properties are done.

Cell isolation plays a very vital role in the diagnostics and research of chronic diseases. It helps in drug discovery by studying the behaviour of the cells and their response to disease and drugs. This technique of drug discovery helps to generate medicines that can be used for the treatment of various diseases such as cancer, genetic disorders, and autoimmune diseases. With incidents of chronic diseases on the rise across the world, the research, drug development, and clinical trials on various cell-based therapies also need to be increased. Therefore, the demand for cell isolation market will also have a boost.

This will be a significant factor fuelling the growth of the cell isolation market. The cell separation techniques play a vital role in personalized medicines, which are used for early detection of disease, selection of appropriate treatment, and determining the prognosis of the therapy. All these factors have contributed towards a positive dynamic growth curve of this market, and it is expected to keep growing in the coming years.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/2237

Further key findings from the report suggest:

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/cell-isolation-market

Segments covered in the report:

For the purpose of this study, Reports and Data have segmented the cell isolation market on the basis of product, cell type, technique, application, end use and region:

Product (Revenue in USD Billion, 2018 - 2026)


Reagents, kits, media, and sera





Flow cytometers

Filtration systems

Magnetic-activated cell separator systems

Delivery Mode Type (Revenue, USD Million; 20162026)

Human cells

Differentiated Cells

Stem Cells

Animal Cells

Technique (Revenue in USD Billion, 2018 - 2026)

Application (Revenue in USD Billion, 2018 - 2026)

End Use (Revenue in USD Billion, 2018 - 2026)

Order Now: https://www.reportsanddata.com/checkout-form/2237

Regional Outlook (Revenue in USD Million; 20162026)

North America

o U.S.

o Canada


o Germany

o France

o UK

o Spain

o Italy

o Rest of the Europe

Asia Pacific

o China

o India

o Japan

o Rest of Asia-Pacific

Middle East & Africa

o Latin America


About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

See original here:
Cell Isolation Market To Reach USD 18.26 Billion By 2026 | Reports And Data - GlobeNewswire

Seattle Genetics Announces Health Canada Approval of ADCETRIS (Brentuximab Vedotin) in Combination with Chemotherapy in Frontline CD30-Expressing…


- Approval of Supplemental New Drug Submission for ADCETRIS in Combination with CHP Chemotherapy in Frontline CD30-Expressing Peripheral T-Cell Lymphoma based on Positive Phase 3 ECHELON-2 Clinical Trial Results -

Seattle Genetics, Inc. (SGEN) today announced that Health Canada has approved the supplemental New Drug Submission that expands the use of ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) chemotherapy for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30. The approval is based on positive results of the phase 3 ECHELON-2 clinical trial that compared ADCETRIS plus CHP to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Health Canada granted a Priority Review Designation for this submission. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on the surface of several types of PTCL.

The Health Canada approval of ADCETRIS (brentuximab vedotin) in combination with CHP chemotherapy in newly diagnosed CD30-expressing peripheral T-cell lymphoma represents the first major advance for Canadian patients with PTCL in decades, said Kerry Savage, M.D., Medical Oncologist at the BC Cancer Agency, Professor of Medicine at the University of British Columbia and investigator on the ECHELON-2 clinical trial. The approval is based on the ECHELON-2 clinical trial that demonstrated ADCETRIS (brentuximab vedotin) plus CHP regimen was superior for both progression-free survival and all key secondary endpoints, including overall survival, when compared to the standard of care CHOP chemotherapy.

The current standard of care for initial treatment of peripheral T-cell lymphoma is multi-agent chemotherapy, which results in low complete remission rates and poor progression-free and overall survival. ECHELON-2 is the first randomized trial to demonstrate an overall survival benefit over established standard therapy, making it a meaningful advance in the treatment of these rare lymphomas, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. With this new indication for ADCETRIS, physicians and eligible patients in Canada now have access to this important new regimen for treating frontline CD30-expressing peripheral T-cell lymphoma, another milestone supporting our plans to continue to expand ADCETRIS globally to patients in need.

In May 2019, Health Canada approved the supplemental New Drug Submission that expanded the use of ADCETRIS in combination with AVD (Adriamycin, vinblastine and dacarbazine) chemotherapy in patients with previously untreated Stage IV Hodgkin lymphoma (HL) based on the results of the phase 3 ECHELON-1 clinical trial.

About T-Cell Lymphomas

There are more than 60 subtypes of non-Hodgkin lymphomas which are broadly divided into two major groups: B-cell lymphomas, which develop from abnormal B-lymphocytes, and T-cell lymphomas, which develop from abnormal T-lymphocytes. There are many different forms of T-cell lymphomas, some of which are extremely rare. T-cell lymphomas can be aggressive (fast-growing) or indolent (slow-growing). PTCL accounts for approximately 10 percent of non-Hodgkin lymphoma cases in the U.S. and Europe and may be as high as 24 percent in parts of Asia.


ADCETRIS is being evaluated broadly in more than 70 clinical trials in CD30-expressing lymphomas. These include three completed phase 3 trials: ECHELON-2 trial in frontline peripheral T-cell lymphomas, ECHELON-1 in previously untreated Hodgkin lymphoma, and ALCANZA in cutaneous T-cell lymphoma.

ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

ADCETRIS injection for intravenous infusion has received FDA approval for six indications in adult patients with: (1) previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone, (2) previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine, (3) cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation, (4) cHL after failure of auto-HSCT or failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates, (5) sALCL after failure of at least one prior multi-agent chemotherapy regimen, and (6) primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.

Story continues

Health Canada granted ADCETRIS approval with conditions in 2013 for patients with (1) HL after failure of autologous stem cell transplant (ASCT) or after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates and (2) sALCL after failure of at least one multi-agent chemotherapy regimen. Non-conditional approval was granted for (3) post-ASCT consolidation treatment of patients with HL at increased risk of relapse or progression in 2017, (4) adult patients with pcALCL or CD30-expressing MF who have received prior systemic therapy in 2018, (5) for previously untreated patients with Stage IV HL in combination with doxorubicin, vinblastine, and dacarbazine in 2019, and (6) for previously untreated adult patients with sALCL, peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumors express CD30, in combination with cyclophosphamide, doxorubicin, prednisone in 2019.

ADCETRIS received conditional marketing authorization from the European Commission in October 2012. The approved indications in Europe are: (1) for the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma following ASCT, or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, (2) for the treatment of adult patients with relapsed or refractory sALCL, (3) for the treatment of adult patients with CD30-positive Hodgkin lymphoma at increased risk of relapse or progression following ASCT, (4) for the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy and (5) for the treatment of adult patients with previously untreated CD30-positive Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine and dacarbazine).

ADCETRIS has received marketing authorization by regulatory authorities in 73 countries for relapsed or refractory Hodgkin lymphoma and sALCL. See select important safety information, including Boxed Warning, below.

Seattle Genetics and Takeda are jointly developing ADCETRIS. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and Takeda are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where Takeda is solely responsible for development costs.

About Seattle Genetics

Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has a late-stage pipeline including enfortumab vedotin for metastatic urothelial cancer, currently being reviewed for approval by the FDA, and tisotumab vedotin in clinical trials for metastatic cervical cancer, which utilize our proprietary ADC technology. In addition, tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer. We are also leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Switzerland. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

ADCETRIS (brentuximab vedotin) U.S. Important Safety Information

BOXED WARNING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.


ADCETRIS concomitant with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).

Warnings and Precautions

Most Common (20% in any study) Adverse Reactions: Peripheral neuropathy, fatigue, nausea, diarrhea, neutropenia, upper respiratory tract infection, pyrexia, constipation, vomiting, alopecia, decreased weight, abdominal pain, anemia, stomatitis, lymphopenia and mucositis.

Drug Interactions

Concomitant use of strong CYP3A4 inhibitors or inducers has the potential to affect the exposure to monomethyl auristatin E (MMAE).

Use in Specific Populations

Moderate or severe hepatic impairment or severe renal impairment: MMAE exposure and adverse reactions are increased. Avoid use.

Advise males with female sexual partners of reproductive potential to use effective contraception during ADCETRIS treatment and for at least 6 months after the final dose of ADCETRIS.

Advise patients to report pregnancy immediately and avoid breastfeeding while receiving ADCETRIS.

Please see the full Prescribing Information, including BOXED WARNING, for ADCETRIS here.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the potential utilization of ADCETRIS (brentuximab vedotin) for previously untreated adult patients with systemic anaplastic large cell lymphoma, peripheral T-cell lymphoma-not otherwise specified or angioimmunoblastic T-cell lymphoma, whose tumours express CD30 in Canada and the therapeutic potential of ADCETRIS in this indication. Actual results or developments may differ materially from those projected or implied in these forward-looking statements due to factors such as utilization and adoption of the approved treatment regimen by prescribing physicians, competitive conditions including the availability of alternative treatment regimens, the availability and extent of reimbursement, the risk of adverse events, and adverse regulatory action. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191125005237/en/

Seattle Genetics Announces Health Canada Approval of ADCETRIS (Brentuximab Vedotin) in Combination with Chemotherapy in Frontline CD30-Expressing...

Macular Degeneration Treatment Market and its Future Outlook and Trend During the Period of 2019 2026 – The Chicago Sentinel

The sources of data and information mentioned in the MACULAR DEGENERATION TREATMENT report are very reliable and include websites, annual reports of the companies, journals, and mergers which are checked and validated by the market experts. It also includes strategic profiling of top players in the market, wide-ranging analysis of their core competencies, and their strategies

This Market Report by Material, Application, and Geography Global Forecast to 2026 is a professional and comprehensive research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe, Middle East and Asia-Pacific)

Click Here to Get Sample Report Of Macular Degeneration Treatment Market

Here are the names of top key players which are covered in this report: Neurotech, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Adverum, Allergan, Regeneron Pharmaceuticals, Inc, STEMCELL Technologies Inc, IVERIC bio, Kubota Pharmaceutical Holdings Co., Ltd, Bayer AG, Novartis AG, Sanwa Kagaku Kenkyusho Co., Ltd, others

By Types (Wet Macular Degeneration, Dry Macular Degeneration), Treatment (Drugs, Surgery), Route of Administration (Oral, Injectable and Others), End- Users (Hospitals, Homecare, Specialty Clinics, Ophthalmic Clinic and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

According to the statistics published in the press release by Neurotech, an estimated population of Macular telangiectasia type 2 is nearly around 1 per 22,000 worldwide. High demand of novel treatment and huge investment on research and development are drivers for market growth.

Regional Analysis

North America: US, Canada, Mexico

South America: Brazil, Argentina, Rest of South America

Asia-Pacific: Japan, China, South Korea, India, Australia, Singapore, Malaysia

Middle East and Africa: South Africa, Egypt, Saudi Arabia, United Arab Emirates, Israel

Purchase this Report with 30% Discount at https://databridgemarketresearch.com/request-a-discount/global-bricklaying-robot-market

Benefits of Purchasing Data Bridge Market Research Report

Research Methodology:

In September 2019, Adverum reported positive 24-week clinical data from the first cohort of patients treated with a one-time intravitreal (IVT) dose of ADVM-022, gene therapy in the OPTIC phase I clinical trial in wet age-related macular degeneration (wet AMD).The trial demonstrated sustained improvements in retinal anatomy. The clinical trial results indicating potentially significant clinical benefits for patients with wet age-related macular degeneration.

In February 2019, Neurotech received Fast Track designation from the FDA for NT-501 or Renexus, a encapsulated cell therapy for the treatment of macular telangiectasia type 2 (MacTel). The FDA Fast Track designation enables the company to accelerate the development process which helps patients to have access on the treatment as quickly as possible.


Table of Contents















Read Complete Details@ https://www.databridgemarketresearch.com/toc/?dbmr=global-macular-degeneration-treatment-market OR Call On +1 888 387 2818(US)

Reasons to Purchase this Report

See original here:
Macular Degeneration Treatment Market and its Future Outlook and Trend During the Period of 2019 2026 - The Chicago Sentinel

Stem Cell Therapies Market research to Witness a Healthy Growth during 2015 2025 – Lake Shore Gazette

Stem cells are undifferentiated biological cells, and having remarkable potential to divide into any kind of other cells. When a stem cell divides, each new cell will be a new stem cell or it will be like another cell which is having specific function such as a muscle cell, a red blood cell, brain cell and some other cells.

There are two types of stem cells

Stem cells harvested from umbilical cord blood just after birth. And this cells can be stored in specific conditions. Stem cells also can be harvest from bone marrow, adipose tissue.

Embryonic cells can differentiate into ectoderm, endoderm and mesoderm in developing stage. Stem cells used in the therapies and surgeries for regeneration of organisms or cells, tissues.

Stem cells are used for the treatment of Gastro intestine diseases, Metabolic diseases, Immune system diseases, Central Nervous System diseases, Cardiovascular diseases, Wounds and injuries, Eye diseases, Musculoskeletal disorders.

Request Sample Report @https://www.futuremarketinsights.com/reports/sample/rep-gb-1087

Harvesting of Adult cell is somewhat difficult compare to embryonic cells. Because Adult cells available in the own body and it is somewhat difficult to harvest.

Stem Cell TherapiesMarket: Drivers and Restraints

Technology advancements in healthcare now curing life threatening diseases and giving promising results. Stem Cell Therapies having so many advantages like regenerating the other cells and body organisms. This is the main driver for this market. These therapies are useful in many life threatening treatments. Increasing the prevalence rate of diseases are driven the Stem Cell Therapies market, it is also driven by increasing technology advancements in healthcare. Technological advancements in healthcare now saving the population from life threatening complications.

Increasing funding from government, private organizations and increasing the Companies focus onStem cell therapiesare also driven this market

However, Collecting the Embryonic Stem cells are easy but Collecting Adult Stem cell or Somatic Stem cells are difficult and also we have to take more precautions for storing the collected stem cells.

Download Data Set @https://www.futuremarketinsights.com/askus/rep-gb-1087

Stem Cell TherapiesMarket: Segmentation

Stem Cell Therapies are segmented into following types

Based on treatment:

Based on application:

Based on End User:

Stem Cell TherapiesMarket: Overview

With rapid technological advantage in healthcare and its promising results, the use of Stem Cell Therapies will increase and the market is expected to have a double digit growth in the forecast period (2015-2025).

Stem Cell TherapiesMarket: Region- wise Outlook

Depending on geographic regions, the global Stem Cell Therapies market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa.

The use of Stem Cell Therapies is high in North America because it is highly developed region, having good technological advancements in healthcare setup and people are having good awareness about health care. In Asia pacific region china and India also having rapid growth in health care set up. Europe also having good growth in this market.

Request to View TOC @https://www.futuremarketinsights.com/toc/rep-gb-1087

Stem Cell TherapiesMarket: Key Players

Some of the key players in this market are

Stem Cell Therapies Market research to Witness a Healthy Growth during 2015 2025 - Lake Shore Gazette

Regenerative Medicine Market: Rising Government Investments in Regenerative Medicine Research – The Chicago Sentinel

Biologics Market growth is largely driven by the rising prevalence of chronic diseases and genetic disorders, growing government investments in regenerative medicine research, and the increasing number of regenerative medicine companies globally.

What the Market Looks Like?

Predicted to grow at a CAGR of 23.8% during the forecast period, the global Regenerative Medicine market is estimated to reach USD 38.7 Billion by the end of 2024. North America to grow at the highest rate during the forecast period. North America has both public and private banks that store a limited number of cells and tissues.

Rising government investments in regenerative medicine research

The need for newer, better therapies for diseases/conditions such as cancer, diabetes, dermal diseases, musculoskeletal diseases, burns, and CVD has resulted in an overall increase in the number of research activities as well as the availability of funding for regenerative medicine research. Currently, several government organizations are investing in research institutes to develop advanced technologies in cell therapy. For instance, in January 2016, the government of Canada granted USD 20 million to the Centre for Commercialization of Regenerative Medicine. This grant will be utilized for establishing a stem-cell therapy development facility in Toronto, Canada. In addition, the NIH funding for the development of cell therapies is increasing significantly, annually.

The US is the major participant in the global regenerative medicine research sector, with various organizations in the country supporting regenerative medicine research. Since 2004, the California Institute of Regenerative Medicine (CIRM) has sponsored over 750 projects, with over USD 2.98 billion in funding. The NIH also funded USD 4.8 billion for research and development under the 21st Century Cures Act, including funding for regenerative medicine, for a ten-year period starting in 2017. Furthermore, under the 21st Century Cures Act, the FDA launched novel procedures in 2017, such as the regenerative medicine advanced therapy (RMAT) designation, to accelerate the access to the most promising regenerative medicine therapies.

Owing to the importance of regenerative medicine, the number of government and private bodies supporting R&D activities related to stem cell therapeutics and regenerative medicine is expected to increase further in the coming years.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579

What Drives the Market?

The growth of the global market for Regenerative Medicine is primarily influenced by the following factors:

The other factors supporting market growth include the growing pipeline of regenerative medicine products and the rising demand for organ transplantation.

Geographical growth scenario of Regenerative Medicine Market

Geographically, the Regenerative Medicine market has been studied for North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest market share in 2018 and is also projected to witness the highest growth in the forecast period.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=65442579

Leading market players and strategies adopted

The prominent players in the Regenerative Medicine market include Kite Pharma (US), Novartis (Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US).

About MarketsandMarketsMarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the Growth Engagement Model GEM. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write Attack, avoid and defend strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead.

MarketsandMarketss flagship competitive intelligence and market research platform, Knowledge Store connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact Us:Mr. Shelly SinghMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL60062USA: +1-888-600-6441Email:sales@marketsandmarkets.comVisit Our Website: https://www.marketsandmarkets.com

Visit link:
Regenerative Medicine Market: Rising Government Investments in Regenerative Medicine Research - The Chicago Sentinel

Research Antibodies and Reagents Market Worth $14.56 Billion by 2025 – Exclusive Report by Meticulous Research – GlobeNewswire

London, Nov. 25, 2019 (GLOBE NEWSWIRE) -- According to a new market research report Research Antibodies and Reagents Market by Product (Reagent [Sample Preparation (Media, Probe, Buffer), Antibody Production Reagent], Antibody [Type, Source, Research Area]), Technology (Western Blot, ELISA), Application, End-User - Global Forecast to 2025, published by Meticulous Research, the research antibodies and reagents market is expected to grow at a CAGR of 6% from 2019 to 2025 to reach $14.56 billion by 2025.

Research antibodies act as a vital tool in laboratory techniques that are conducted for research purpose. Due to their high specificity and sensitivity, antibodies and associated reagents make an exquisite tool aiding in the detection of molecules and its analysis, which enables the researchers to draw conclusions related to drug target, disease occurrence, and immune system pathways. The rising proteomics and genomic research studies, increase in the funding for research activities, and growing industry-academia collaborations are the key factors driving steady growth in the global research antibodies and reagents market.

Request Sample Report:https://www.meticulousresearch.com/request-sample-report/cp_id=5055

In recent years, the funding for healthcare research projects has increased significantly. According to the Research America, investment in medical and health research and development by the U.S. has increased by 18.1% between 2014 and 2017. In 2017, total expenditure on medical and health R&D in the U.S. was $182.3 billion. Industry, including pharmaceutical, medical technology, biotechnology and health IT companies, accounted for the largest share of the U.S. investment in medical and health R&D over the reporting period. Similarly, in Europe, according to European Union (EU), Horizon 2020 program was launched in 2016, with an investment of $88.5 billion (80 billion); of which around 10% (~$9 billion) was utilized for healthcare sector. The initiative was aimed at developing and supporting personalized medicine projects. Also, during the period of 2014-2016, the European Commission invested more than $2.7 billion (2.4 billion) in projects that supported innovation in personalized medicine. Therefore, such increase in funding has led to rise in research activities in pharmaceutical and biotechnology industries, thereby boosting the demand for research antibodies and reagents.

The research antibodies and reagents market study presents historical market data in terms of value (2017 and 2018), estimated current data (2019), and forecasts for 2025 by product, technology, application, end user, and geography. The study also evaluates industry competitors and analyzes their market share at the global and regional levels.

Based on product, reagents segment is estimated to account for the largest share of the overall research antibodies and reagents market in 2019 and is slated to grow at the fastest CAGR during the forecast period. The large share of this segment is attributed to recurrent use of reagents in many research assays and techniques and increasing developments in research reagents.

Based on technology, western blotting segment is estimated to account for the largest share of the overall research antibodies and reagents market in 2019. This is mainly attributed to increasing focus on initiating developments in diagnosis and therapy procedures and rising research funding for biomarker discovery and antibody & cell-based products. On the other hand, Enzyme-linked Immunosorbent Assay (ELISA) is slated to grow at the fastest CAGR during the forecast period due to increasing use of ELISA technology for screening of active ingredients and validation of obtained hits in drug discovery.

Based on application, proteomics segment is estimated to hold the largest share of the overall research antibodies and reagents market in 2019. This is mainly attributed to the increase in search for ideal candidates for use as anti-cancer drugs, need for designing more effective drugs, assessment of drug efficacy and patient response, and development of antibodies especially monoclonal antibodies. Growing use of proteomic technologies in development of target-based therapies also supports the large share and growth in this market.

Based on end user, pharmaceutical and biotechnology companies segment is estimated to hold the largest share of the overall research antibodies and reagents market in 2019, due to high adoption of research antibodies & reagents in proteomics research and drug discovery and development programs. Rising focus of industry players on developing innovative therapeutics for chronic diseases is contributing to the growth of this market. On the other hand, the demand for research antibodies from contract research organizations (CROs) is slated to grow fastest during the forecast period, mainly due to increase in outsourcing activities by pharmaceutical industries to CROs.

The report also includes extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2016-2019). The research antibodies and reagents market has witnessed number of partnerships & agreements in the recent years. For instance, in January 2018, Abcam plc (U.K.) entered into an agreement with Roche to facilitate licensing of product portfolio of Spring Bioscience Corporation to Abcam for research use only (RUO) applications, which includes recombinant antibodies. Similarly, in October 2017, Bio-Techne Corporation (U.S.) entered into an agreement with Joint Consortia Framework for the development of research antibodies & antibody-based reagents. Similarly, in January 2018, Illumina, Inc. (U.S.) launched iSeq 100 sequencing system, which offers exceptional data accuracy, at a low capital cost.

The global research antibodies and reagents market is highly fragmented with the presence of key players, such as, Abcam plc (U.K.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.),GE Healthcare (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann La-Roche Ltd (Switzerland), Rockland Immunochemicals Inc. (U.S.), Johnson & Johnson (U.S.), Agilent Technologies, Inc. (U.S.), Eli Lily and Company (U.S.), Becton Dickinson and Company (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), GenScript Biotech Corporation (U.S.), Lonza (Switzerland), Bio-Techne Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Santa Cruz Biotechnology, Inc. (U.S.), and BioLegend, Inc.(U.S.) among others.

Browse key industry insights spread across 280 pages with 256 market data tables & 61 figures & charts from the report:https://www.meticulousresearch.com/product/research-antibodies-reagents-market-5055/

Scope of the Report:

Research Antibodies and Reagents Market, by Product

Research Antibodies and Reagents Market, by Technology

Research Antibodies and Reagents Market, by Application

Research Antibodies and Reagents Market, by End User

Research Antibodies and Reagents Market, by Geography

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5055

Related Reports:Immunoassay Market by Product (Kits and Reagents, Analyzers, Software), Platform (Chemiluminescence, Radioimmunoassays) Application (Infectious Diseases, Cardiology), End-User (Hospitals, Academic Laboratories), and Geography - Global Forecast to 2025, read more:https://www.meticulousresearch.com/product/immunoassay-market-4982/

Cell Culture Market by Product [Consumables (Media, Reagents, Sera, FBS, Antibiotics, Growth Factor, Buffer), Equipment (Bioreactor, Centrifuge)], Application (Biopharmaceutical, Cancer, Stem Cell), and End User (Pharma, Research)- Global Forecast to 2024, read more:https://www.meticulousresearch.com/product/cell-culture-market/

About Meticulous Research

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to details.

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.

With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Follow this link:
Research Antibodies and Reagents Market Worth $14.56 Billion by 2025 - Exclusive Report by Meticulous Research - GlobeNewswire

Visiongain Report Offers Transformative Insights on the $3.2bn Protein Expression Market – PRNewswire

LONDON, Nov. 25, 2019 /PRNewswire/ -- The global protein expression market is estimated at $1.8bn in 2018. Visiongain estimated that the prokaryotic expression system accounted for 40.0% of the global protein expression market.

How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 201-page report you will receive 70 tables and 115 figures all unavailable elsewhere.

The 201-page Visiongain report provides clear detailed insight into the global protein expression market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-protein-expression-market-forecast-to-2029/#download_sampe_div

Report Scope

Global Protein Expression Market forecaststo 2029

Global Protein Expression Market forecaststo 2029by Expression System: Cell-free Expression System Prokaryotic/ Bacterial Expression System Yeast Cell Expression Systems Algal-based Expression Systems Insect Cell Expression Systems Mammalian Cell Expression Systems

Global Protein Expression Market forecasts to 2029by Product & Services: Reagents Expression Vectors Competent Cells Instruments Services

Global Protein Expression Market forecasts to 2029by Application: Therapeutic Applications Industrial Application Research Application

Global Protein Expression Market forecaststo 2029by End-User: Pharmaceutical and Biotechnology Companies Academic Research Institutes Contract Research Organizations (CROs)

Global Protein Expression Market forecaststo 2029by National Market: North America: US, Canada EU: Germany, France, UK, Italy, Spain Asia: Japan, China, India

Assessment of selectedleading companies that hold major market shares in the protein expression industry: Agilent Technologies Bio-Rad Technologies EMD Milipore New England Biolabs, Inc. Oxford Expression Technologies, Ltd. Promega Corporation Qiagen NV Takara Bio, Inc. Thermo Fisher Scientific, Inc.

Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the protein expression market. Moreover, this report discussesfactors that drive and restrain the protein expression market.

Key Questions Answered by This Report: What is the current size of the protein expression market? How much will this market be worth from 2019-2029? What will be the main drivers and restraints for this market? What are the different segments of the protein expression market? How much will each of these segments be worth during 2019-2029 and how will their market shares change during this period? What are the largest national protein expression markets? How much will these markets be worth from 2019-2029? How will the emerging markets affect the market shares of the mature markets? What are the most prominent companies in the market? What products and services do they offer, and what are the main features and advantages of them? What are the main trends affecting the market? What technologies will increase in prominence between 2019 and 2029? What are the advantages of these technologies? What are the main strengths, weaknesses, opportunities and threats for the market? What are the social, technological, economic and political factors affecting the market?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-protein-expression-market-forecast-to-2029/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

Abgenex Agilent Technologies Inc.Anthem BiosciencesAstraZenecaBayerBio-Rad TechnologiesBiotechnology Industry Research Assistance Council BioTek InstrumentsBrammer BioBristol-Myers Squibb Cancer Research UK Centers for Disease Control and Prevention Clontech Laboratories, Inc. Department of Biotechnology EMD MilliporeGIMDx, Inc. HD Biosciences Co., Ltd.Icagen, Inc. IncellDx, IncInnoCore PharmaceuticalsInSphero AG Institute for Molecular Medicine Finland JanssenLabcyte Inc.LikardaLuxcel Biosciences LtdMerckMerck & Co., IncNew England Biolabs Inc.Novo Nordisk Foundation Center for Biosustainability On Target Co., Ltd. OriGeneOxford Expression Technologies LtdPharmaceutical Research and Manufacturers of America Promega CorporationQiagen NVSanofiSciGenomSigma-Aldrich CorporationSino BiologicalsTakara Bio Inc.Takeda Pharmaceutical Company Technical University of Denmark Thermo Fisher Scientific Inc.UCBWaferGen Bio-systems, Inc. World Health Organization

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Immunochemistry Reagents, Analyzers and Test Kits Market 2019-2029

Pharmaceutical Contract Manufacturing Market 2019-2029

Global Medical Device Contract Manufacturing Market Forecast 2019-2029

3D Printing for Healthcare Market Report 2019-2029

Global Stem Cell Technologies and Applications Market 2019-2029

SOURCE Visiongain

Go here to read the rest:
Visiongain Report Offers Transformative Insights on the $3.2bn Protein Expression Market - PRNewswire

Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions – Business Wire

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (Immune-Onc), a privately held cancer immunotherapy company, announced today the addition of several industry veterans to its executive team and advisory boards and the promotion of An Song, Ph.D. to Chief Scientific Officer from Senior Vice President of Development Sciences. Dr. Paul Woodard joins Immune-Onc from Bellicum Pharmaceuticals, Inc. where he most recently served as Senior Vice President, Clinical and Medical Affairs.

We are thrilled to add such seasoned and strategic individuals to the executive and advisory teams guiding Immune-Onc through its next phase of growth as a clinical stage company, said Charlene Liao, Ph.D., Co-founder and Chief Executive Officer of Immune-Onc. As our Chief Medical Officer, Paul brings the right combination of deep expertise in oncology paired with proven strategic leadership and experience building teams and functions in a startup environment. The appointment of An to Chief Scientific Officer is a reflection of the contributions she has already made to the company in her current role and a recognition of the value that her experience will bring in guiding the translation of our science into development.

I cant imagine a more exciting time to join Immune-Onc, said Dr. Woodard. I was first drawn to the novel science underlying the portfolio. As I learned more about Immune-Onc and their authentic passion for improving patient lives, it became clear to me that this was a company that I wanted to contribute to in a meaningful way with the goal of bringing much needed new treatment options to people with hard-to-treat cancers like acute myeloid leukemia.

About Paul Woodard, M.D.

As Chief Medical Officer, Dr. Woodard will be responsible for clinical leadership and medical oversight of the Immune-Onc portfolio. These activities will include review and input of IND submissions, clinical protocol development and medical oversight of Immune-Onc trials, and oversight of internal and external clinical development, biometrics, safety, and regulatory functions and compliance.

Dr. Woodard has an extensive hematology and oncology background gained in academia and industry. His academic experience focused on pediatric hematopoietic stem cell transplantation and hematologic disorders at world-renowned institutions, including St. Jude Childrens Research Hospital, University of California, San Francisco, and Childrens Hospital, Los Angeles. In addition to patient care, at St. Jude, Dr. Woodard was responsible for Phase 1/2 trials in pediatric hematopoietic stem cell transplantation for malignant and non-malignant disorders.

Prior to joining Immune-Onc, Dr. Woodard worked on a wide range of drug development projects in solid tumors, hematologic malignancies, and non-malignant hematologic disorders. At Exelixis, Dr. Woodard worked on small molecule tyrosine kinase inhibitors for solid tumors. At Amgen, Dr. Woodard was the global development leader for Nplate (romiplostim) in immune thrombocytopenia and myelodysplastic syndromes. At Genentech, Dr. Woodard was the global development team leader for Tecentriq (atezolizumab) in hematologic malignancies and was an integral team member for the development of Tecentriq combinations in solid tumors (including triple negative breast cancer) and hematologic malignancies. At Bellicum, Dr. Woodard was the Senior Vice President of Clinical and Medical Affairs, with oversight of the companys cellular therapy portfolio and clinical trials in hematologic malignancies and solid tumors.

Dr. Woodard earned his medical degree at the University of North Carolina and completed his residency at the University of Virginia and fellowships in pediatric hematology-oncology at the University of North Carolina and in pediatric blood and marrow transplantation at the University of Minnesota.

About An Song, Ph.D.

Dr. Song joined Immune-Onc in July 2018 as Senior Vice President of Development Sciences. In the newly created role of Chief Scientific Officer, Dr. Song will have overall accountability for translational development of Immune-Oncs portfolio and strategic oversight of research and antibody engineering.

Dr. Song is a translational scientist with 22 years of experience across basic research and drug development in oncology, autoimmunity, metabolic, infectious, and neurodegenerative diseases. Dr. Song joins Immune-Onc from Genentech where, as a Senior Director in BioAnalytical Sciences, she led the Assay Development and Technology group for the companys large molecule portfolio globally and was a member of numerous scientific review bodies within the Genentech Research and Early Development (gRED) organization. During her 16-year tenure at Genentech, Dr. Song contributed to, and oversaw 40+ IND/CTA and BLA/MAA regulatory filings for products including Rituxan, Avastin, Herceptin, Lucentis, Kadcyla and Tecentriq. In addition, Dr. Song played a significant role in the development and approval of Ocrevus.

Dr. Song received her Ph.D. in Biochemistry & Molecular Biology from Indiana University and completed a postdoctoral fellowship in immunology, followed by a faculty position as Assistant Professor (Research) at Stanford University. As an active member of the American Association of Pharmaceutical Scientists (AAPS), Dr. Song has served as an executive member of the Biotech Section and chair of the Therapeutic Product Immunogenicity (TPI) Focus Group/Community.


In addition, Immune-Onc bolstered its cadre of advisors with the appointment of Zhengbin (Bing) Yao, Ph.D. to its Board of Directors and Gregory Cosma, Ph.D. to its Scientific Advisory Board. Both Bing and Greg bring significant experience in helping early-stage companies navigate the complexity of drug development, commented Dr. Liao. Bing and Gregs perspectives are invaluable in supporting Immune-Onc in our mission to deliver transformative therapies to cancer patients.

About Zhengbin (Bing) Yao, Ph.D.

Dr. Yao has more than 20 years of experience in the biopharmaceutical industry, with a proven track record of successfully leading the discovery and development of multiple biotherapeutics. Dr. Yao is currently Chairman of the Board and CEO of Viela Bio. Prior to this role, he was Senior Vice President, Head of Respiratory, Inflammation and Autoimmune iMED at MedImmune/AstraZeneca. During his tenure at MedImmune, he played key leadership roles in the development and approval of three novel biologics for autoimmune, respiratory, and immune-oncology indications. Previously, Dr. Yao also served as Senior Vice President, Head of Immuno-Oncology Franchise, AstraZeneca, as well as CEO for WuXi-MedImmune Joint Venture. Dr. Yao joined MedImmune in 2010 from Genentech, where he was the Head of Project Team Leaders for Immunology, Infectious Diseases, Neuroscience, and Metabolic Disease. He was Vice President and Head of Research for Tanox, before the company was acquired by Genentech in 2007. Dr. Yao also held several positions of increasing responsibility at Aventis and Amgen and currently serves on the Board of Directors for NexImmune. Dr. Yao received his Ph.D. in Microbiology and Immunology from the University of Iowa, followed by postdoctoral work at Immunex.

About Gregory Cosma, Ph.D.

As a former executive at Genentech and Bristol-Myers Squibb, Dr. Cosma has a long track record of success leading companies in translating science into approved therapies. As Vice President of Research and Early Development at Genentech from 2010-2019, Dr. Cosma led the Safety Assessment organization comprising Toxicology, Pathology, Product Quality and Occupational Toxicology and Nonclinical Operations. He also chaired the Genentech Development Review Committee (DRC), overseeing nonclinical development of the Genentech pipeline from Research to First-in-Human studies. While at Bristol-Myers Squibb from 2003-2010, Dr. Cosma held roles as the Executive Director for Drug Safety Evaluation and as the Therapeutic Area Head for Metabolic Diseases. Prior to these roles, Dr. Cosma was a Research Fellow at Pharmacia-Pfizer and an assistant professor in the College of Veterinary Medicine and Biomedical Sciences at Colorado State University. Dr. Cosma earned his doctorate in Pharmacology/Toxicology at the University of Kansas.


Immune-Onc Therapeutics, Inc. (Immune-Onc) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Its lead program, an antibody targeting LILRB4, is being developed to treat acute myeloid leukemia and other cancers. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit http://www.immune-onc.com.

Follow this link:
Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions - Business Wire

A sound theoretical mechanism and clinical indication are not enoughthe case of Platelet Rich Plasma for Achilles tendon ruptures – The BMJ – The BMJ

A global industry has grown around using platelet rich plasma (PRP) in sports medicine. Its appeal has been heightened by use in high profile athletes. PRP has evolved over millennia. As natures most refined healing elixir of minute vessels packed with bioactive proteins, it stood every chance of being that new accelerant of tissue healing.

To produce PRP, the patients own blood is processed, usually in a specialised centrifuge, to produce a solution containing a supraphysiological concentration of platelets. But where does it lie in the spectrum between another fashionable application and a proven novel regenerative therapy? We set out to sift the evidence from the enthusiasm with an open mind, and to place some robust research quality markers that would allow proper critique.

Our 2016 paper in The BMJ discussed the uncertainties in this area, and looked at how effective platelet rich plasma injections are in treating musculoskeletal soft tissue injuries. At the time there had been 29 randomised controlled trials, but it was difficult to draw clear conclusions about efficacy, because of PRP use in heterogeneous musculoskeletal conditions, underpowered studies, and poor reporting. [1]

Furthermore, few trials included an analysis of PRP content or quality, yet PRP had been adopted widely in clinical practice. Many commercially available PRP preparation devices had US Food and Drug Administration approval based on device performance and safety, but not clinical efficacy. [2] However, animal and cellular research was providing some encouraging evidence in support of a theoretical mechanism and potential effect. [3]

It was because of the latter that we embarked upon the PATH-2 trial to investigate the efficacy of PRP. We identified acute Achilles tendon rupture as a suitable human injury to study, as it is common and patients often experience a frustrating recovery, due to slow tissue healing and recovery of muscle function. The case for robust evaluation was clear, however the complexity and cost of a randomised controlled trial were significant. We first conducted a pilot with embedded mechanistic studies to address the limitations of previous trials, then recruited to the largest trial of PRP to date in 19 UK hospitals. To standardise PRP, we provided the same specialist centrifuge to each hospital, standard operating procedures and training in blood sample handling, and tested all blood and PRP samples at a central laboratory. Recruiting participants in busy trauma clinics, and handling the masking of the PRP or dry needle injection were some of the challenges. For our findings to be unequivocal the primary outcome needed to be an instrumented muscle performance test by a blinded assessor; that ensured objective alongside patient-reported outcomes.

The results of the PATH-2 trial are now published in The BMJ, and show that when subjected to robust evaluation, there is no evidence of patient benefit from injecting high quality PRP for acute Achilles tendon ruptures.

It took years of development, trialling, and evaluation, to deliver this negative finding. Some may think that this was a misplaced effort and resources. But safety and efficacy are paramount as no intervention is without risk or cost, even if autologous. This may not be the end of the PRP story. We assumed natures recipe of bioactive proteins released from activated platelets was the ideal, but perhaps some ingredients have more potency than others. There is a clear sense, however, that the many other current musculoskeletal PRP applications now need to be subjected to similar evaluation. There is also a wider message about adopting innovations into practice and the balance with robust clinical trial evaluation. Enthusiasm for using promising technologies and a strong theoretical justification from pre-clinical research are insufficient. This is especially important where new interventions are not subjected to the same regulations as new medicines.

David J Keene, NIHR Postdoctoral Research Fellow, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. @davidkeenePT

Keith Willett, Professor of Orthopaedic Trauma Surgery, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Competing interests: See research paper.


View post:
A sound theoretical mechanism and clinical indication are not enoughthe case of Platelet Rich Plasma for Achilles tendon ruptures - The BMJ - The BMJ